Mohammedi K, Marre M, Alhenc-Gelas F
Cardiovasc Diabetol. 2024; 23(1):453.
PMID: 39709470
PMC: 11662484.
DOI: 10.1186/s12933-024-02544-0.
Harder J, Hodgin J, Kretzler M
Kidney Dis (Basel). 2016; 1(3):194-203.
PMID: 26929927
PMC: 4768943.
DOI: 10.1159/000439196.
Chen H, Wei F, Wang L, Wang Z, Meng J, Jia L
Int J Clin Exp Med. 2015; 8(3):3662-70.
PMID: 26064261
PMC: 4443095.
Lin Y, Pan J, Jiang M, Tan J, Zhong W, Gong T
Med Sci Monit. 2014; 20:1596-603.
PMID: 25196797
PMC: 4166221.
DOI: 10.12659/MSM.892111.
Araki S
Clin Exp Nephrol. 2013; 18(2):230-3.
PMID: 24026386
DOI: 10.1007/s10157-013-0862-0.
Apolipoprotein-defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort.
Jenkins A, Yu J, Alaupovic P, Basu A, Klein R, Lopes-Virella M
J Diabetes Complications. 2013; 27(5):447-53.
PMID: 23850262
PMC: 4064461.
DOI: 10.1016/j.jdiacomp.2013.06.002.
Genome-wide association studies of chronic kidney disease: what have we learned?.
OSeaghdha C, Fox C
Nat Rev Nephrol. 2011; 8(2):89-99.
PMID: 22143329
PMC: 4769862.
DOI: 10.1038/nrneph.2011.189.
Role of apolipoprotein E in renal damage protection.
Bonomini F, Rodella L, Moghadasian M, Lonati C, Coleman R, Rezzani R
Histochem Cell Biol. 2011; 135(6):571-9.
PMID: 21573735
DOI: 10.1007/s00418-011-0815-1.
Genetic diversity of the apolipoprotein E gene and diabetic nephropathy: a meta-analysis.
Li Y, Tang K, Zhang Z, Zhang M, Zeng Z, He Z
Mol Biol Rep. 2010; 38(5):3243-52.
PMID: 20177792
DOI: 10.1007/s11033-010-9999-z.
Association of APOE polymorphism with chronic kidney disease in a nationally representative sample: a Third National Health and Nutrition Examination Survey (NHANES III) Genetic Study.
Chu A, Parekh R, Astor B, Coresh J, Berthier-Schaad Y, Smith M
BMC Med Genet. 2009; 10:108.
PMID: 19852818
PMC: 2770999.
DOI: 10.1186/1471-2350-10-108.
The relationship of the apolipoprotein E gene polymorphism Turkish Type 2 diabetic patients with and without nephropathy.
Erdogan M, Eroglu Z, Biray C, Karadeniz M, Cetinkalp S, Kosova B
J Endocrinol Invest. 2009; 32(3):219-22.
PMID: 19542737
DOI: 10.1007/BF03346455.
Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway.
Sethi S, Gamez J, Vrana J, Theis J, Bergen 3rd H, Zipfel P
Kidney Int. 2009; 75(9):952-60.
PMID: 19177158
PMC: 2738640.
DOI: 10.1038/ki.2008.657.
Lipids and diabetic nephropathy.
Rosario R, Prabhakar S
Curr Diab Rep. 2006; 6(6):455-62.
PMID: 17118229
DOI: 10.1007/s11892-006-0079-7.
A retrospective study on the influence of apolipoprotein e and serum lipids in progressive renal failure.
Roussos L, Ehle P, Floren C
Int Urol Nephrol. 2005; 37(2):329-34.
PMID: 16142566
DOI: 10.1007/s11255-004-5536-0.
Cost-effective strategies in the prevention of diabetic nephropathy.
Rippin J, Barnett A, Bain S
Pharmacoeconomics. 2004; 22(1):9-28.
PMID: 14720079
DOI: 10.2165/00019053-200422010-00002.
Co-inheritance of specific genotypes of HSPG and ApoE gene increases risk of type 2 diabetic nephropathy.
Liu L, Xiang K, Zheng T, Zhang R, Li M, Li J
Mol Cell Biochem. 2003; 254(1-2):353-8.
PMID: 14674716
DOI: 10.1023/a:1027364121738.
Apolipoprotein E gene polymorphism is not a strong risk factor for diabetic nephropathy and retinopathy in Type I diabetes: case-control study.
Shcherbak N
BMC Med Genet. 2001; 2:8.
PMID: 11495633
PMC: 37310.
DOI: 10.1186/1471-2350-2-8.
